Dietary glucarate and treatment of tumors
|Calcium D-Glucarate and Tumors||Darrell Miller||05/27/05|
May 27, 2005 09:40 AM
Author: Darrell Miller (firstname.lastname@example.org)
Subject: Calcium D-Glucarate and Tumors
Dietary glucarate as anti-promoter of 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis. Walaszek Z; Hanausek-Walaszek M; Minton J P; Webb T E Carcinogenesis (1986 Sep), 7(9), 1463-6. Journal code: 8008055. ISSN:0143-3334. United States. Journal; Article; (JOURNAL ARTICLE) written in English. PubMed ID 3091283 AN 86298867 MEDLINE
Using as a criterion the inhibition of serum beta-glucuronidase activity, dietary calcium D-glucarate is shown to serve as an efficient slow-release source in vivo of D-glucaro-1,4-lactone, the potent endogenous inhibitor of this enzyme. Using the 7,12-dimethylbenz[a]anthracene model of mammary tumor induction in rats it is shown for the first time that feeding the rats calcium D-glucarate-supplemented diet after treatment with the carcinogen, inhibits tumor development by over 70%. Supportive evidence is presented for the theory that calcium D-glucarate inhibits or delays the promotion phase of mammary carcinogenesis by lowering endogenous levels of estradiol(estrogen) and precursors of 17-ketosteroids. Therefore, dietary glucarate can be used to lower blood and tissue levels of beta-glucuronidase, and in turn of those carcinogens and promoting agents which are excreted, at least in part, as glucuronide conjugates.
VitaNet ® Staff